Enquirer Consulting Group

BPX Buyer Map

Prepared for David Hamilton | BPX | October 2026

As of Oct 7, 2026

BPX sells consulting and its ION platform to pharma and biotech teams, in R&D portfolio leadership, medical affairs, leadership and internal communications, and commercial. Those teams sit inside the companies developing drugs and biologics. This page sizes the companies leading open drug and biologic trials with a US site, by how many studies they run and how far along they are, the US locations in the same industries, and the roles that usually own the work. It says nothing about which of them BPX already works with.

Companies leading an open drug or biologic trial with a US site

1,800

Industry lead sponsors, open studies.

Companies leading five or more open studies

160

Where a portfolio view takes the most work.

Companies with a phase 3 trial open

590

Late-stage programs.

Companies whose open trials are all phase 1 or 2

1,100

Earlier-stage developers, often with smaller teams.

Trials running now

Industry-led studies in the federal trial registry, read on Oct 7, 2026.

Open means recruiting, not yet recruiting, enrolling by invitation or active and no longer recruiting, with at least one US site and a drug or biologic intervention. A company is counted once, with all of its open studies. These 6,000 studies are the US share of each company's work, not its whole pipeline. A combined phase 2 and 3 study counts as phase 3. Rounded figures may not add to the total.
Open studies a company leads	Companies	Of those, with a phase 3 open
20 or more	about 30	about 30
5 to 19	130	110
2 to 4	550	240
1	1,100	210
All	1,800	590

US locations in the same industries

US drug, biologic and biotech research locations by staff size, mid-March 2023.

Industry codes are our closest match to each group. One company with ten sites counts ten times. The biotechnology research row also holds contract research organizations and labs that run no drug program of their own.
Group	All locations	Under 10 staff	10 to 49 staff	50 to 249 staff	250+ staff
Drug makers	1,400	570	380	320	180
Biologic product makers	440	170	about 100	about 100	about 80
Biotechnology research and development	5,700	3,700	1,200	530	140

What no public count reaches

Groups this page cannot size, said in words rather than shown as a number.

The size of a company's medical affairs, portfolio or communications team is not published anywhere we can count. Companies selling approved drugs with no open US trial sit outside the trial counts, though any US sites they run in these industries sit inside the location counts. Programs still before their first trial are the same. Each of these is built by name, company by company.

Who owns the work

The roles that commonly own or weigh in on the work your site describes. Titles vary by company, and at the smaller ones one person often holds several.

Team	Roles
R&D portfolio	Head of portfolio management, head of R&D operations, chief of staff to the head of R&D, program management office lead
Medical affairs	Head of medical affairs, head of medical communications, head of field medical, medical excellence or operations lead
Leadership and internal communications	Chief of staff to the chief executive, head of internal communications, head of strategy
Commercial	Head of commercial operations, head of commercial insights and analytics, head of sales operations

Three openings

Where the counts point.

Companies running many studies at once.

About 160 companies lead five or more open US studies, and about 30 of them lead 20 or more. Your site describes portfolio leadership for organizations with no consolidated view across 50+ R&D or transformation projects. Of the groups on this page, these companies come closest to that description, the largest of them most of all. The approach goes to the head of portfolio management or R&D operations.

Companies with a phase 3 open and no phase 4.

About 540 companies have an open US phase 3 trial and no open phase 4 study. Late-stage programs are often where medical affairs and KOL work builds ahead of a launch, and your site lists newsletters for medical affairs teams and a module for KOL and HCP engagement. The approach goes to the head of medical affairs.

Companies leading one open study.

About 1,100 companies lead a single open US study. Many are small developers, and at those the board deck, the pipeline update and internal news often sit with the chief executive and a small leadership team, so one conversation can cover what your site sells as several solutions.

Denominators, definitions and sources

Trial counts come from the federal trial registry, read on Oct 7, 2026. They count interventional studies with an intervention of the registry's drug or biological type, that are open and name at least one US site, and whose lead sponsor is industry. Company names are matched after removing legal suffixes, so a company listed under two spellings, or a parent and its subsidiary, may count twice.
Some companies have neither an early-phase-only nor a phase 3 profile (for example only phase 4 studies, or only studies with no phase given), so those two counts do not add up to the company count.
Location counts are establishments in the federal annual count of business establishments by industry, 2023, national file, all legal forms. An establishment is one physical location with paid employees. Staff is paid employees at the location in the mid-March 2023 pay period. Where the file withholds a size cell, the withheld locations are recovered as the group total less the published cells.
Industry codes 325412 pharmaceutical preparation manufacturing; 325414 biological product manufacturing, except diagnostic; 541714 research and development in biotechnology, except nanobiotechnology.
Built from public registries, counts banded deliberately. Figures of 100 and over are rounded to two significant figures, figures from 10 to 99 to the nearest ten.

The named version of this page, the actual companies inside a row, is built one row at a time. If you want to walk through a row together, pick a time at cal.com/ecg. Prepared by Ben Beattie, ben@enquirerconsulting.com.

Enquirer Consulting Group | enquirerconsulting.com